Use of galectin-3 for assessing cardiac function in prediabetes and type 2 diabetes mellitus (T2DM) needs to be established. Within the Gutenberg Health Study cohort (N = 15,010, 35–74 years) patient characteristics were investigated regarding galectin-3 levels. Prognostic value of galectin-3 compared to NT-proBNP concerning cardiac function and mortality was assessed in individuals with euglycaemia, prediabetes and T2DM in 5 years follow-up. Higher galectin-3 levels related to older age, female sex and higher prevalence for prediabetes, T2DM, cardiovascular risk factors and comorbidities. Galectin-3 cross-sectionally was related to impaired systolic (β − 0.36, 95% CI − 0.63/− 0.09; P = 0.008) and diastolic function (β 0.014, 95% CI 0.001/0.03; P = 0.031) in T2DM and reduced systolic function in prediabetes (β − 0.34, 95% CI − 0.53/− 0.15; P = 0.00045). Galectin-3 prospectively related to systolic (β − 0.656, 95% CI − 1.07/− 0.24; P = 0.0021) and diastolic dysfunction (β 0.0179, 95% CI 0.0001/0.036; P = 0.049), cardiovascular (hazard ratio per standard deviation of galectin-3 (HR_perSD) 1.60, 95% CI 1.39–1.85; P < 0.0001) and all-cause mortality (HR_perSD 1.36, 95% CI 1.25–1.47; P < 0.0001) in T2DM. No relationship between galectin-3 and cardiac function was found in euglycaemia, whereas NT-proBNP consistently related to reduced cardiac function. Prospective value of NT-proBNP on cardiovascular and all-cause mortality was higher. NT-proBNP was superior to galectin-3 to assess reduced systolic and diastolic function.

需要确定使用 galectin-3 评估前驱糖尿病和 2 型糖尿病 (T2DM) 的心脏功能。在 Gutenberg 健康研究队列（N = 15,010, 35-74 岁）中，研究了有关 galectin-3 水平的患者特征。在 5 年的随访中，评估了血糖正常、糖尿病前期和 T2DM 个体中半乳糖凝集素 3 与 NT-proBNP 在心脏功能和死亡率方面的预后价值。较高的半乳糖凝集素 3 水平与年龄较大、女性以及糖尿病前期、T2DM、心血管危险因素和合并症的较高患病率有关。Galectin-3 横截面与 T2DM 和舒张功能受损 (β - 0.36, 95% CI - 0.63/- 0.09; P = 0.008) 和舒张功能 (β 0.014, 95% CI 0.001/0.03; P = 0.031) 和糖尿病前期患者的收缩功能降低 (β - 0.34, 95% CI - 0.53/- 0.15; P = 0. 00045)。Galectin-3 与收缩期 (β - 0.656, 95% CI - 1.07/- 0.24; P = 0.0021) 和舒张功能障碍 (β 0.0179, 95% CI 0.0001/0.036; P = 0.049)、心血管（每标准的风险比）前瞻性相关半乳糖凝集素3的偏差（HR_perSD ) 1.60, 95% CI 1.39–1.85; P < 0.0001）和T2DM 的全因死亡率（HR _perSD 1.36, 95% CI 1.25–1.47; P < 0.0001）。在血糖正常时未发现半乳糖凝集素 3 与心功能之间存在相关性，而 NT-proBNP 始终与心功能降低有关。NT-proBNP 对心血管和全因死亡率的前瞻性价值更高。NT-proBNP 在评估收缩和舒张功能降低方面优于 galectin-3。